Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CTXR with free AI briefings, catalyst countdowns, and dilution alerts.

CTXR · Citius Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$17M Cash on Hand
10.2mo Cash Runway
Follow CTXR by email Get an email when CTXR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CTXR, unsubscribe in one click. Privacy

📣 What CTXR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Denileukin Diftitox (E7777)
FDA approved Aug 2024 · Lymphir
Persistent or Recurrent Cutaneous T-Cell Lymphoma Phase 3 · NCT01871727 Completed
Combination - CITI-002 (high dose) Hemorrhoids Phase 2 · NCT05348200 Completed

Also used in these trials (approved or third-party drugs, not CTXR's own candidates): Hydrocortisone Acetate, Lidocaine Hydrochloride, Lidocaine, Halobetasol Propionate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CTXR holds $17M in cash and short-term investments (as of Jun 30, 2026) and burns about $5M/quarter from operations, an estimated runway of 10.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CTXR files for a raise →

👥 Who Owns CTXR

Insiders 100% Institutions (38 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Citius Pharmaceuticals, Inc.
10% owner
Insider 66,049,615 240.60% 2026-05-15
CVI Investments, Inc. 5%+ holder (13G) 3,008,529 10.96% 2026-06-30
Leonard L Mazur
Chief Executive Officer, Director · +5.96M options
Insider 410,214 1.49% 2025-08-08
Myron Z Holubiak
Vice Chairman, Director · +3.28M options
Insider 79,690 0.29% 2025-08-08
Jaime Bartushak
Chief Financial Officer · +1.67M options
Insider 60,353 0.22% 2024-11-07
Carol Webb
Director · +875,000 options
Insider 11,835 0.04% 2024-11-07
Eugene Myron Holuka
Director · +875,000 options
Insider 2,367 0.01% 2024-11-07

Share count 27,452,570 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CTXR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CTXR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.